Your browser doesn't support javascript.
loading
Sorafenib in renal cell carcinoma
Pakistan Journal of Pharmaceutical Sciences. 2014; 27 (1): 203-208
em Inglês | IMEMR | ID: emr-143002
ABSTRACT
Cancer is among most important causes of death in recent decades. Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments. The purpose of this work is to provide an overview and also deeper insight to renal cell carcinoma and the steps which have been taken to reach more specific treatment and target therapy, in this type of cancer by developing most effective agents such as Sorafenib. To achieve this goal hundreds of research paper and published work has been overviewed and due to limitation of space in a paper just focus in most important points on renal cell carcinoma, treatment of RCC and clinical development of Sorafenib. The information presented this paper shows the advanced of human knowledge to provide more efficient drug in treatment of some complicated cancer such as RCC in promising much better future to fight killing disease.
Assuntos
Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Carcinoma de Células Renais / Ensaios Clínicos como Assunto / Niacinamida / Receptores de Fatores de Crescimento do Endotélio Vascular / Inibidores de Proteínas Quinases / Antineoplásicos Limite: Humanos Idioma: Inglês Revista: Pak. J. Pharm. Sci. Ano de publicação: 2014

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Carcinoma de Células Renais / Ensaios Clínicos como Assunto / Niacinamida / Receptores de Fatores de Crescimento do Endotélio Vascular / Inibidores de Proteínas Quinases / Antineoplásicos Limite: Humanos Idioma: Inglês Revista: Pak. J. Pharm. Sci. Ano de publicação: 2014